# Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer

**Authors:** Yael Bar, Steven J Isakoff, Seth A Wander

PMC · DOI: 10.1093/jncics/pkaf092 · 2025-10-26

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** breast cancer (MESH:D001943)

---
Source: https://tomesphere.com/paper/PMC12557322